Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia

Scandinavian Journal of Urology and Nephrology

Volumn 30, Issue 5, 1996, Pages 373-377

  Hansen, Bo Jesper ^a,f   Meyhoff, Hans Henrik ^b   Nordling, Joørgen ^c   Mensink, Han J A ^d   Mogensen, Peter ^a   Larsen, Erik Højkjær ^e  

^a BISPEBJERG HOSPITAL   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f NONE   (Denmark)

Author keywords

Benign prostatic hyperplasia (BPH); Natural history; Pharmacological treatment; Placebo

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL;

EID: 0029804248     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365599609181313     Document Type: Article

References (24)

1. Aso Y, Boccon-Gibod L, Calais Da Silva F, et al. Subjective response, objective response, impact on quality of life. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S & Murphy G, eds. The International Consultation on Benign Prostatic Hyperplasia (BPH). Geneva: WHO, 1991: 87-90.
2. Balslev Jørgensen J, Jensen KM-E, Mogensen P. Longitudinal observations on normal and abnormal voiding in men over the age of 50 years. Br J Urol 1993; 72: 413-420.
3. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495-506.
4. Beecher HK. The powerful placebo. JAMA 1955; 159: 1602-1606.
5. Birkhoff JD, Wiederhorn AR, Hamilton ML, Zinsser HH. Natural history of benign prostatic hypertrophy and acute retention. Urology 1976; 7: 48-52
6. Brody H. The lie that heals: The ethics of giving placebos. Ann Intern Med 1982; 97: 112-118.
7. Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982; 20: 602-608.
8. Duncan BM, Garraway WM. Prostatic surgery for Benign prostatic hyperplasia: Meeting the expanding demand. Br J Urol 1993; 72: 761-765.
9. The finasteride study group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-299.
10. Fischer HK, Dlin BM. The dynamics of placebo therapy: A clinical study. Am J Med Sci 1956; 232: 504-512.
11. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469-471.
12. Garraway WM, Armstrong C, Auld S, King S, Simpson RJ. Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1993; 24: 313-318.
13. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-1191.
14. Hansen BJ, Nordling J, Mensink HJA, Walter S, Meyhoff HH and the ALFECH study group. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994; (Suppl 157): 169-175.
15. Jardin A, Bensadoun H, Delauche-Cavaillier MC, Attali P, and the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-1461.
16. Kleijnen J, de Craen AJM, van Everdingen J, Krol L. Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet 1994; 344: 1347-1349.
17. Lasagna L, Laties VG, Dohan JL. Further studies on the "pharmacology" of placebo administration. J Clin Invest 1958; 37: 533-537.
18. Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: The United States Experience. Br J Urol 1992; 70(Suppl 1): 2-9.
19. Lindahl O, Lindwall L. Is all therapy just placebo effect? Metamedicine 1982; 3: 255-259.
20. Madsen PO, Iversen P. A point system for selecting operative candidates. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer Verlag, 1983: 763-765.
21. Roehrborn CG. The assessment of medical treatment for benign prostatic hyperplasia. In: Kurth K, Newling DWW, eds EORTC Genitourinary Group Monograph. 12. Benign prostatic hyperplasia, recent progress in clinical research and practice. New York: Wiley-Liss 1994; PCBR 386: 175-190.
22. Sommer, P, Nielsen KK, Bauer T, et al. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 1990; 65: 155-160.
23. Wein AJ. Evaluation of treatment response in benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 631-640.
24. Wolf S. Effects of suggestion and conditioning on the action of chemical agents in human objects - the pharmacology of placebos. J Clin Invest 1950; 29: 100-109.